#APOC3
October #JCLSpotlight: Single-dose ION775, a GalNAc-conjugated siRNA targeting APOC3, lowers triglycerides for up to 12 months in moderate hypertriglyceridemia
Read more: https://ow.ly/gnZh5107tnI
November 17, 2026 at 7:38 PM
In patients with severe hypertriglyceridemia, plozasiran, a small interfering RNA that targets APOC3 messenger RNA, reduced triglyceride levels and risk of acute pancreatitis. Full results of the phase 3 SHASTA-3 and SHASTA-4 trials and Research Summary: https://nej.md/4iv82y3
November 10, 2026 at 6:00 PM
Severe hypertriglyceridemia is associated with a risk of acute pancreatitis. Plozasiran, a small interfering RNA targeting APOC3 messenger RNA, lowers triglyceride levels and may mitigate risk. Research findings from two phase 3 trials are summarized in a new video. https://nej.md/3Ud1lZF
November 8, 2026 at 8:00 PM
New research about Plozasiran, a small interfering RNA targeting APOC3 messenger RNA, examine its impact on patients with Hypertriglyceridemia. You can read more in The New England Journal of Medicine.

Read Here: https://ow.ly/L7Zv5104fBT

#Plozasiran #MedicalResearch #CardioHealth
November 6, 2026 at 8:00 PM
🧬 Triglyceride drug cut pancreatitis

In two trials, 91% and 93% on plozasiran got blood fat under 500 mg per deciliter, against about half on placebo. Pancreatitis fell from 5 to 1 per 100 patient-years. Fewer painful attacks.

🔗 doi.org/10.1056/nejmoa2610014

#Medicine #Genetics 🧪
Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis | NEJM
Severe hypertriglyceridemia is associated with an increased risk of acute pancreatitis. Plozasiran, a small interfering RNA targeting APOC3 messenger RNA, lowers triglyceride levels and potentially...
doi.org
November 5, 2026 at 5:43 AM
“Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis.”
Publié ce jour dans le @nejm.org.
#MedSky #EndoSky
www.nejm.org/doi/full/10....
Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis | NEJM
Severe hypertriglyceridemia is associated with an increased risk of acute pancreatitis. Plozasiran, a small interfering RNA targeting APOC3 messenger RNA, lowers triglyceride levels and potentially...
www.nejm.org
November 5, 2026 at 2:28 PM
In patients with severe hypertriglyceridemia, plozasiran, a small interfering RNA that targets APOC3 messenger RNA, reduced triglyceride levels and risk of acute pancreatitis. Full results of the phase 3 SHASTA-3 and SHASTA-4 trials: https://nej.md/4iv82y3
November 4, 2026 at 10:10 PM
#CLLS Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at…

https://www.stocktitan.net/news/CLLS/cellectis-presents-preclinical-data-highlighting-efficient-apoc3-z5rupwdtacuf.html?utm_source=stocktitan-bluesky&utm_medium=social
Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
Cellectis (CLLS) presented preclinical data for .HEAL-101, its gene-editing candidate for severe hypertriglyceridemia, at the European Society of Gene and Cell Therapy congress.The candidate targets APOC3, a driver of elevated triglycerides. In human liver cells, mean editing was approximately 90%, without DNA double-strand breaks at the target site. In mice with humanized livers and normal lipid levels, a single intravenous injection achieved approximately 65% mean human APOC3 editing, reaching up to 70%. In a separate mouse disease model, APOC3 fell 67% ± 12% (mean ± standard deviation); single-dose triglyceride reduction was highlighted at 76%. Editing was detected in the liver, with no significant activity in other tissues analyzed.Cellectis plans a Phase 1 investigator-initiated trial in China, with preliminary clinical data expected in the second half of 2027.
www.stocktitan.net
October 27, 2026 at 7:15 AM
Effects of HA1, a probucol analogue, and APOC3 siRNA on lipoprotein and amyloid β — explained in one short video. Follow for more like this.

#effectsprobucol #biophoton #coherance #energy #mind #workout #logic #meta #molecule #gym #quantum #metacognition
October 14, 2026 at 8:02 PM
A clear look at Effects of HA1, a probucol analogue, and APOC3 siRNA on lipoprotein and amyloid β — no jargon.

#effectsprobucol #metacognition #logic #mind #meta #quantum #workout #coherance #photon #science #energy #fyp
October 11, 2026 at 8:03 PM
Effects of HA1, a probucol analogue, and APOC3 siRNA on lipoprotein and amyloid β — explained in one short video. Save this for later.

#effectsprobucol #coherance #meta #logic #science #metacognition #dna #cellular #workout #mind #yeet #came
October 3, 2026 at 12:03 AM
$CLLS shifts to in vivo gene-editing for APOC3 & PCSK9, aims for Ph1 data in 2027-28; ends lasme-cel/eti-cel work to extend cash runway to H2 2028.

www.biopharmcatalyst.com/news/2026/bi...
Daily Updates 09/14/26
export-download.canva.com
September 14, 2026 at 8:30 PM
Gynxz - Live on Twitch
Phas Rollover challenge Insanity-Apoc3 / !bingo / !phas | Streaming phasmophobia.
www.twitch.tv
September 11, 2026 at 10:08 PM
APOC3-Targeting Drug Has Benefits in Severe Hypertriglyceridemia
APOC3-Targeting Drug Has Benefits in Severe Hypertriglyceridemia
APOC3-Targeting Drug Has Benefits in Severe Hypertriglyceridemia mosbey@crf.org Thu, 09/10/2026 - 16:48 L.A. McKeown SHASTA-3/4 trial data show plozasiran, like olezarsen, can drastically lower triglycerides and the risk of acute pancreatitis.
www.tctmd.com
September 10, 2026 at 8:57 PM
Here's the crux of it. Non-HDL-C, ApoB, TRL-C(triglyceride rich lipoprotein) and ApoC3. 20-26% reduction in ApoB & non-HDL-C is approaching moderate intensity statin reduction. ApoC3 decrease matches the drop in TRL-C(they move together) Basically a large scale clear out of atherogenic particles!
August 30, 2026 at 3:08 PM
That leads to the other calling Reta what it is, at minimum a moderate intensity statin drug. That's fun since it was designed for weight loss and diabetic control!

As noted it also functions like drugs from other lipid lowering therapeutics namely fibrates, ApoC3 and ANGPTL3 inhibitors
August 30, 2026 at 3:08 PM
PXD070672 🚨

APOE2/4 and APOC3/4 Mice: Proteomic comparison of different heterozygous APOO genotypes

🚨 New dataset alert! 🚨
August 29, 2026 at 11:00 PM
STEAP3 variation also mapped to several apolipoproteins (including APOA1, APOC3, APOE), linking RBC iron handling to lipid oxidation and vesiculation pathways, potentially bridging neurodegenerative disease biology to RBC iron metabolism with systemic oxidative stress.
November 19, 2025 at 8:24 PM
This will end up as a long form blog post eventually but it's remarkable that this one drug acts on multiple drug-able targets(HMG-COA, ApoC3, ANGPTL3/8) by itself to lower lipids in addition to all its other benefits.
Full 80 week retatrutide obesity data will be revealed in 45 days!

I want to highlight a couple things besides weight loss from phase 2 that were shocking at the time and will be MORE shocking in phase 3 data.

For my cardiology & lipid nerds this thread is for you!

1/
April 23, 2026 at 12:51 PM
So reductions in ApoC3 and ANGPTL3/8 are allowing systemic clearance of these highly atherogenic particles, while reductions in ANGPTL4/8 reduce your body's ability to *store* lipids. This should mean a reduction in ApoB as well.

And yep.

(And that's a statin-esque ApoB reduction!)
April 22, 2026 at 3:57 PM
And these graphics are mostly from published data showing the ANGPTL3/8 and ApoC3 reductions mirror the triglycerides, LDL and TRL reductions. But there's a reason this is happening. Look at ANGPTL4/8, that's responsible for storing triglycerides in fat cells. It drops too.
April 22, 2026 at 3:57 PM
Broadly oversimplifying here but blocking both things reduce triglycerides, but ANGPTL 3/8 reduces LDL cholesterol and ApoC3 reduces TRL-C(Triglyceride rich lipoprotein cholesterol) or "remnant cholesterol" too

That's visualized in these slides.

Both LDL and TRL are considered highly atherogenic.
April 22, 2026 at 3:57 PM
And before someone says this is weight loss mediated, 1.) it's not. 2.) because weight loss was similar between the two drugs despite Reta being a shorter trial 3.) because glucagon is lipolytic & 4.) there's some deep mechanisms at play here. Enter ApoC3 and ANGPTL 3/8
April 22, 2026 at 3:57 PM
RNAi milestone: REDEMPLO (plozasiran).

Quarterly siRNA targeting APOC3 is now approved US+Canada for FCS. Phase 3: ~80% median triglyceride drop + fewer pancreatitis events.

More → future.xsbrt.com#/f/RNAiTrigl...
FutureLens — Curated Forecasts, Odds & Timelines
Explore curated forecasts with evidence, scenario odds, and clear timelines.
future.xsbrt.com
January 6, 2026 at 12:46 AM